AI Article Synopsis
- * Recent clinical trials show that transplanting islet cells derived from iPSCs or ESCs could lead to more effective and accessible treatment options for individuals with type 1 diabetes.
- * The breakthroughs in this area might also benefit people with type 2 diabetes in the future, expanding treatment possibilities even further.
Article Abstract
Advancements in regenerative medicine, particularly through the use of induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs), are garnering substantial attention as potential solutions to the limited availability of donors, leading to prolonged waiting periods for people with type 1 diabetes who require transplantation of pancreatic islets from deceased donors. The promising outcomes from recent clinical trials suggest that transplantation of iPSC- or ESC-derived islet cells could pave the way for more effective and broadly accessible treatment options. This progress holds potential not only for individuals with type 1 diabetes but may also extend to type 2 diabetes treatment in the future.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jdi.14366 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!